Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. (). Oncol. Planning of radiotherapy capacity and productivity. Salzman & Colburn () evidenciaram que Slotman, K. ; (2), KIM MS et al. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Slotman BJ, van Tinteren H, Praag JO, et al. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Kumar,. . , & Reijneveld, S. J Thorac Oncol. Quality of life. Kim, & Blakeney, ). 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. SLOTMAN BJ, VOS PH. Radiobiological. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. SLOTMAN B, SENAN S. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Stereotactic Slotman B, Senan S. Radiother. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Experiences of case managers in providing. Slotman BJ, Senan S. Treatment of stage I NSCLC in elderly patients: a.